BMS 986263

Drug Profile

BMS 986263

Alternative Names: ND-L02-s0201

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nitto Denko
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatic fibrosis
  • Preclinical Liver cirrhosis
  • No development reported Fibrosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Fibrosis(In volunteers) in USA (IV, Injection)
  • 20 Oct 2017 Preclinical trials in Cirrhosis in Japan (IV) before October 2017
  • 20 Oct 2017 Efficacy, adverse events and pharmacokinetics data from a phase Ib/II trial in Hepatic fibrosis presented at the The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top